Sofinnova Investments related stories
All articles and analysis
VC-backed Sorbent Therapeutics expands board of directorsSorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent's backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.
- Teva agrees to buy VC-backed Labrys for up to $825 mln
sraeli pharmaceutical company Teva Pharmaceutical Industries has agreed to acquire Labrys Biologics for $200 million in upfront payment in cash as well as up to $625 million in payments based on achievement of certain pre-launch milestones. Based in San Mateo, Calif., Labrys is a biotech firm focused on treating migraine. It was backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.
- Spark Therapeutics attracts $72.8 mln Series B
Spark Therapeutics has closed $72.8 million in Series B financing. Sofinnova Ventures led the round with participation from Brookside Capital, Deerfield Management Company, Rock Springs Capital, T. Rowe Price Associates, Wellington Management Company, The Children's Hospital of Philadelphia and two unnamed healthcare funds. Based in Philadelphia, Spark Therapeutics is a developer of gene therapy products that treat rare, debilitating diseases.
- Coherus BioSciences nabs $55 mln Series C
Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.
- Sorbent Therapeutics closes first tranche in $15 mln Series D
Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has closed a $6.5 million tranche in a $15 million Series D financing. The investors were CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.
- Principia Biopharma nabs $50 mln Series B funds
Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma's board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.
- Principia Biopharma nabs $50 mln Series B funds
Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma's board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.
- NuCana grabs $57 mln Series B funds
NuCana has raised $57 million in Series B funding. Sofinnova Ventures led the round with participation from Sofinnova Partners, Morningside Ventures, Alida Capital International and the Scottish Investment Bank, the investment arm of Scottish Enterprise. In addition to the funding, James Healy and Gerald Chan, co-founder and chairman of Morningside Ventures respectively, have been added to NuCana's board of directors. Based in Edinburgh, NuCana is an biopharmaceutical firm focused on anti-cancer medicines.
- NuCana grabs $57 mln Series B funds
NuCana has raised $57 million in Series B funding. Sofinnova Ventures led the round with participation from Sofinnova Partners, Morningside Ventures, Alida Capital International and the Scottish Investment Bank, the investment arm of Scottish Enterprise. In addition to the funding, James Healy and Gerald Chan, co-founder and chairman of Morningside Ventures respectively, have been added to NuCana's board of directors. Based in Edinburgh, NuCana is an biopharmaceutical firm focused on anti-cancer medicines.
- VC-backed Versartis raises $126 mln for IPO
Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.